Breaking News Instant updates and real-time market news.

ABT

Abbott

$41.17

0.58 (1.43%)

07:48
10/19/16
10/19
07:48
10/19/16
07:48

Abbott reports Q3 Worldwide Medical Devices sales increased 6.4%

Worldwide Medical Devices sales increased 6.4 percent on a reported basis in the third quarter, including a favorable 0.4 percent effect of foreign exchange, and increased 6.0 percent on an operational basis. Worldwide sales of Vascular products increased 5.2 percent on a reported basis in the third quarter, including a favorable 0.3 percent effect of foreign exchange, and increased 4.9 percent on an operational basis. Sales growth in Vascular products was led by double-digit growth of MitraClip, Abbott's device for the treatment of mitral regurgitation, as Abbott continues to build the market for this first-in-class device. Strong sales growth in Abbott's Endovascular business was driven by vessel closure products and Supera, Abbott's unique stent for the treatment of blockages in the leg. In the quarter, Abbott received U.S. FDA approval for Absorb, the only fully dissolving heart stent. Worldwide Diabetes Care sales increased 11.5 percent on a reported basis in the third quarter, including an unfavorable 1.0 percent effect of foreign exchange, and increased 12.5 percent on an operational basis. International sales growth was driven by continued consumer uptake of FreeStyle Libre, Abbott's revolutionary continuous glucose monitoring system that eliminates the need for finger-sticks. In September, Abbott received U.S. FDA approval for the FreeStyle Libre Pro system, which is designed to help healthcare professionals make better, customized treatment decisions for their patients - and at a significantly lower cost than other professional continuous glucose monitoring systems. During the quarter, Abbott submitted the consumer version of the FreeStyle Libre system for review by the U.S. FDA. The consumer version of the FreeStyle Libre system is designed to eliminate the need for routine finger-sticks and provides glucose data in a simple format that allows people with diabetes to better self-monitor their glucose levels. Worldwide Medical Optics sales increased 4.4 percent on a reported basis in the third quarter, including a favorable 1.9 percent effect of foreign exchange, and increased 2.5 percent on an operational basis. Operational sales growth was driven by continued market uptake of cataract products in the premium intraocular lens segment. In the quarter, Abbott received U.S. FDA approval and launched its TECNIS Symfony intraocular lenses, the first and only lenses in the U.S. that provide a full range of continuous high-quality vision following cataract surgery.

  • 19

    Oct

  • 21

    Oct

  • 06

    Nov

ABT Abbott
$41.17

0.58 (1.43%)

09/29/16
COWN
09/29/16
NO CHANGE
COWN
Outperform
Cowen says views on Dexcom, Insulet not changed by competitor launches
Cowen analyst Doug Schenkel noted that Abbott (ABT) announced yesterday it had received FDA approval for the professional version of its FreeStyle Libre glucose monitoring product and filed the consumer version of Libre, while Medtronic (MDT) also announced FDA approval of its 670G Hybrid Closed Loop system. Schenkel said Abbott's consumer Libre filing comes a few months ahead of his expectations but that Medtronic's timing was in-line with expectations. The analyst said the competitor announcements, which had been expected, do not change his views on DexCom (DXCM), Insulet (PODD), or Tandem Diabetes (TNDM) and he keeps Outperform ratings on all three of those stocks.
09/29/16
ADAM
09/29/16
NO CHANGE
Target $53
ADAM
Buy
Alere risk-reward looks 'quite good' as deal debate nears end, says Canaccord
Canaccord analyst Mark Massaro said he is optimistic that a conclusion of Abbott (ABT) and Alere's (ALR) merger fight is "not far off" and he still believes Abbott will ultimately acquire Alere, though he also thinks the merger may be decided by a judge. Massaro puts a 65% probability on the likelihood the deal closes at the $56 deal price, a 30% chance that Abbott buys Alere at a lower price nearer to $50 per share, and only a 5% chance the deal breaks, making the risk-reward ratio in Alere shares at current levels "quite good," he tells investors. He trimmed his price target on Alere to $53 from $56 an keeps a Buy rating on the stock.
09/29/16
BARD
09/29/16
NO CHANGE
BARD
Dexcom, Insulet could be weighed down by competitive concerns, says Baird
Baird analyst Jeff Johnson said that while the FDA approvals announced yesterday for Abbott's (ABT) FreeStyle Libre Pro and Medtronic's (MDT) 670G were largely anticipated, he believes that both approvals came sooner than most expected, as did news that Abbott also recently filed for FDA approval of its consumer Libre system. The approvals could "change the narrative" in diabetes and could weigh on others in the sector in the near-term, most notably Dexcom (DXCM) and Insulet (PODD), Johnson tells investors. He keeps Neutral ratings on both and maintains an Overweight rating on Tandem Diabetes (TNDM), citing valuation for the difference.
10/11/16
COWN
10/11/16
NO CHANGE
Target $85
COWN
Outperform
Cowen says St. Jude advisory common for the industry
While Dear Doctor letters are never a positive, St. Jude Medical's (STJ) medical device advisory relating to a low rate of premature battery depletion in the high voltage portfolio is common in the Cardiac Rhythm Management industry, Cowen analyst Joshua Jennings tells investors in a research note. The analyst sees limited risk to St. Jude's franchise and still expects the takeover by Abbott Laboratories' (ABT) to close by the end of the year. Jennings keeps an Outperform rating on St. Jude shares with an $85 price target. The stock is down 1% to $80.19 in pre-market trading.

TODAY'S FREE FLY STORIES

VIA

Viacom

$39.15

0.1 (0.26%)

, VIAB

Viacom

$34.11

-0.01 (-0.03%)

16:20
06/25/17
06/25
16:20
06/25/17
16:20
Hot Stocks
Box Office Battle: Fifth 'Transformers' film ekes out $45M in franchise low »

Viacom's (VIA)…

VIA

Viacom

$39.15

0.1 (0.26%)

VIAB

Viacom

$34.11

-0.01 (-0.03%)

TWX

Time Warner

$99.70

0.3 (0.30%)

DIS

Disney

$104.36

0.14 (0.13%)

LGF.A

Lionsgate

$27.07

0.31 (1.16%)

LGF.B

Lionsgate

$25.38

0.34 (1.36%)

FOX

21st Century Fox

$26.93

0.3 (1.13%)

FOXA

21st Century Fox

$27.19

0.22 (0.82%)

SNE

Sony

$38.52

0.11 (0.29%)

CMCSA

Comcast

$39.50

-0.44 (-1.10%)

CMCSK

Comcast

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jun

  • 27

    Jul

  • 03

    Aug

  • 08

    Aug

GSK

GlaxoSmithKline

$44.29

0.13 (0.29%)

14:42
06/25/17
06/25
14:42
06/25/17
14:42
Hot Stocks
GlaxoSmithKline granted Orphan designation for multiple myeloma treatment »

The FDA granted…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BHVN

Biohaven Pharmaceutical

$25.33

-0.13 (-0.51%)

14:40
06/25/17
06/25
14:40
06/25/17
14:40
Hot Stocks
Biohaven granted Orphan designation for Rett syndrome treatment »

The FDA granted Biohaven…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ESALY

Eisai

$56.42

-0.075 (-0.13%)

14:37
06/25/17
06/25
14:37
06/25/17
14:37
Hot Stocks
Eisai unit receives Orphan designation for myelomonocytic leukemia treatment »

The FDA has granted…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PTNR

Partner Communications

$5.25

0.1123 (2.19%)

14:23
06/25/17
06/25
14:23
06/25/17
14:23
Hot Stocks
Partner Communications executes early loan repayments, sees Q2 expense »

Partner Communications…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RARX

RA Pharmaceuticals

$23.01

0.01 (0.04%)

14:21
06/25/17
06/25
14:21
06/25/17
14:21
Hot Stocks
RA Pharma: Presentation on complement inhibitors supports continued development »

Ra Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jun

VSTM

Verastem

$2.32

-0.06 (-2.52%)

14:17
06/25/17
06/25
14:17
06/25/17
14:17
Hot Stocks
Verastem reports long-term follow up data from 'DYNAMO' study »

Verastem announced the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jun

  • 29

    Jun

  • 11

    Jul

BMY

Bristol-Myers

$56.64

-0.69 (-1.20%)

14:09
06/25/17
06/25
14:09
06/25/17
14:09
Hot Stocks
Bristol-Myers reports four-year follow up data from 'ELOQUENT-2' study »

Bristol-Myers Squibb…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jul

  • 24

    Sep

AGIO

Agios Pharmaceuticals

$59.18

1.76 (3.07%)

, CELG

Celgene

$134.31

0.63 (0.47%)

14:05
06/25/17
06/25
14:05
06/25/17
14:05
Hot Stocks
Agios Pharmaceuticals reports new data from Phase 1/2 trial of IDHIFA »

Agios Pharmaceuticals…

AGIO

Agios Pharmaceuticals

$59.18

1.76 (3.07%)

CELG

Celgene

$134.31

0.63 (0.47%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AGIO

Agios Pharmaceuticals

$59.18

1.76 (3.07%)

14:00
06/25/17
06/25
14:00
06/25/17
14:00
Hot Stocks
Agios reports updated Phase 2 data on AG-348, sees 1H18 pivotal program »

Agios Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SNOW

Intrawest Resorts

$23.65

0.04 (0.17%)

13:53
06/25/17
06/25
13:53
06/25/17
13:53
Hot Stocks
Intrawest Resorts says Hart-Scott-Rodino merger waiting period expires »

Intrawest Resorts…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CI

Cigna

$169.61

-1.07 (-0.63%)

13:31
06/25/17
06/25
13:31
06/25/17
13:31
Periodicals
Cigna could gain over 15% by end of next year, Barron's says »

The GOP healthcare plan…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FL

Foot Locker

$48.03

0.53 (1.12%)

, NKE

Nike

$52.85

0.45 (0.86%)

13:26
06/25/17
06/25
13:26
06/25/17
13:26
Periodicals
Potential Nike-Amazon deal another negative for Foot Locker, Barron's says »

A potential direct-sale…

FL

Foot Locker

$48.03

0.53 (1.12%)

NKE

Nike

$52.85

0.45 (0.86%)

AMZN

Amazon.com

$1,003.74

2.44 (0.24%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

  • 28

    Jun

  • 29

    Jun

RHT

Red Hat

$99.42

0.54 (0.55%)

13:15
06/25/17
06/25
13:15
06/25/17
13:15
Periodicals
Red Hat may eke out double-digit returns, Barron's says »

Red Hat investors…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ALXN

Alexion

$126.07

-0.16 (-0.13%)

, UTHR

United Therapeutics

$131.59

-0.11 (-0.08%)

13:01
06/25/17
06/25
13:01
06/25/17
13:01
Periodicals
Alexion, United Therapeutics worth a look, Barron's says »

After the recent jump in…

ALXN

Alexion

$126.07

-0.16 (-0.13%)

UTHR

United Therapeutics

$131.59

-0.11 (-0.08%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

  • 23

    Oct

AIZ

Assurant

$101.25

0.99 (0.99%)

12:32
06/25/17
06/25
12:32
06/25/17
12:32
Periodicals
Assurant could double as investors reevaluate company, Barron's says »

Assurant is shifting…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NCR

NCR Corp.

$38.64

0.09 (0.23%)

12:27
06/25/17
06/25
12:27
06/25/17
12:27
Periodicals
NCR Corp. could gain 30% in a year, Barron's says »

Shares of NCR Corp. could…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ARQL

ArQule

$1.17

0.03 (2.63%)

, NLNK

NewLink Genetics

$7.36

-0.04 (-0.54%)

04:55
06/25/17
06/25
04:55
06/25/17
04:55
Conference/Events
European Hematology Association to hold a conference »

22nd Congress of the EHA…

ARQL

ArQule

$1.17

0.03 (2.63%)

NLNK

NewLink Genetics

$7.36

-0.04 (-0.54%)

BLUE

bluebird bio

$112.00

-6.5 (-5.49%)

XLRN

Acceleron

$34.10

0.15 (0.44%)

BLCM

Bellicum Pharmaceuticals

$13.39

-0.59 (-4.22%)

CRSP

CRISPR Therapeutics

$16.44

0.3 (1.86%)

AGIO

Agios Pharmaceuticals

$59.18

1.76 (3.07%)

CELG

Celgene

$134.31

0.63 (0.47%)

STML

Stemline

$9.10

0.6 (7.06%)

CTIX

Cellceutix

KPTI

Karyopharm

$9.97

0.01 (0.10%)

RARX

RA Pharmaceuticals

$23.01

0.01 (0.04%)

CDTX

Cidara Therapeutics

$6.70

-0.2 (-2.90%)

GBT

Global Blood Therapeutics

$29.85

0.6 (2.05%)

PTLA

Portola Pharmaceuticals

$56.06

17.81 (46.56%)

TGTX

TG Therapeutics

$11.95

-0.05 (-0.42%)

VSTM

Verastem

$2.32

-0.06 (-2.52%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jun

  • 27

    Jun

  • 29

    Jun

  • 29

    Jun

  • 06

    Jul

  • 11

    Jul

  • 26

    Sep

HIMX

Himax

$8.17

-0.02 (-0.24%)

04:55
06/25/17
06/25
04:55
06/25/17
04:55
Conference/Events
Himax management to meet with Roth Captial »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jun

  • 28

    Jun

  • 29

    Jun

AAPL

Apple

$146.28

0.65 (0.45%)

, AMZN

Amazon.com

$1,003.74

2.44 (0.24%)

13:47
06/24/17
06/24
13:47
06/24/17
13:47
Hot Stocks
Week in review: How Trump's policies moved stocks »

Catch up on the top…

AAPL

Apple

$146.28

0.65 (0.45%)

AMZN

Amazon.com

$1,003.74

2.44 (0.24%)

GOOG

Alphabet

$965.59

8.5 (0.89%)

MSFT

Microsoft

$71.21

0.95 (1.35%)

IBM

IBM

$154.11

-0.29 (-0.19%)

MA

MasterCard

$124.01

0.71 (0.58%)

ORCL

Oracle

$50.95

0.65 (1.29%)

VMW

VMware

$90.92

0.48 (0.53%)

INTC

Intel

$34.19

-0.17 (-0.49%)

AKAM

Akamai

$51.30

1.28 (2.56%)

SAP

SAP

$107.48

0.42 (0.39%)

QCOM

Qualcomm

$56.91

0.44 (0.78%)

ADBE

Adobe

$145.41

1.72 (1.20%)

ACN

Accenture

$122.74

0.66 (0.54%)

GOOGL

Alphabet Class A

$986.09

9.47 (0.97%)

LPNT

LifePoint

$65.50

-1.6 (-2.38%)

CYH

Community Health

$9.33

0.06 (0.65%)

THC

Tenet

$18.52

-0.38 (-2.01%)

HCA

HCA Holdings

$86.24

0.1 (0.12%)

UHS

Universal Health

$115.43

0.22 (0.19%)

AET

Aetna

$152.10

-0.88 (-0.58%)

WCG

WellCare

$183.28

-0.32 (-0.17%)

CI

Cigna

$169.61

-1.07 (-0.63%)

HUM

Humana

$238.42

1.42 (0.60%)

ANTM

Anthem

$190.17

-3.19 (-1.65%)

HNT

Health Net

CNC

Centene

$84.15

1.15 (1.39%)

MOH

Molina Healthcare

$71.33

0.02 (0.03%)

UNH

UnitedHealth

$185.25

-1.25 (-0.67%)

REGN

Regeneron

$517.33

-9.2 (-1.75%)

CELG

Celgene

$134.31

0.63 (0.47%)

VRTX

Vertex

$133.50

-2.03 (-1.50%)

ALXN

Alexion

$126.07

-0.16 (-0.13%)

BIIB

Biogen

$280.32

-0.25 (-0.09%)

AMGN

Amgen

$172.50

-1.32 (-0.76%)

X

U.S. Steel

$22.25

1.18 (5.60%)

AKS

AK Steel

$6.65

0.35 (5.56%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

  • 27

    Jun

  • 27

    Jun

  • 28

    Jun

  • 28

    Jun

  • 28

    Jun

  • 29

    Jun

  • 06

    Jul

  • 12

    Jul

  • 13

    Jul

  • 18

    Jul

  • 19

    Jul

  • 19

    Jul

  • 20

    Jul

  • 25

    Jul

  • 25

    Jul

  • 30

    Jul

  • 02

    Aug

  • 14

    Aug

  • 23

    Oct

  • 03

    Feb

HIMX

Himax

$8.17

-0.02 (-0.24%)

04:55
06/24/17
06/24
04:55
06/24/17
04:55
Conference/Events
Himax management to meet with Roth Captial »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jun

  • 28

    Jun

  • 29

    Jun

ARQL

ArQule

$1.17

0.03 (2.63%)

, NLNK

NewLink Genetics

$7.36

-0.04 (-0.54%)

04:55
06/24/17
06/24
04:55
06/24/17
04:55
Conference/Events
European Hematology Association to hold a conference »

22nd Congress of the EHA…

ARQL

ArQule

$1.17

0.03 (2.63%)

NLNK

NewLink Genetics

$7.36

-0.04 (-0.54%)

BLUE

bluebird bio

$112.00

-6.5 (-5.49%)

XLRN

Acceleron

$34.10

0.15 (0.44%)

BLCM

Bellicum Pharmaceuticals

$13.39

-0.59 (-4.22%)

CRSP

CRISPR Therapeutics

$16.44

0.3 (1.86%)

AGIO

Agios Pharmaceuticals

$59.18

1.76 (3.07%)

CELG

Celgene

$134.31

0.63 (0.47%)

STML

Stemline

$9.10

0.6 (7.06%)

CTIX

Cellceutix

KPTI

Karyopharm

$9.97

0.01 (0.10%)

RARX

RA Pharmaceuticals

$23.01

0.01 (0.04%)

CDTX

Cidara Therapeutics

$6.70

-0.2 (-2.90%)

GBT

Global Blood Therapeutics

$29.85

0.6 (2.05%)

PTLA

Portola Pharmaceuticals

$56.06

17.81 (46.56%)

TGTX

TG Therapeutics

$11.95

-0.05 (-0.42%)

VSTM

Verastem

$2.32

-0.06 (-2.52%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jun

  • 24

    Jun

  • 27

    Jun

  • 29

    Jun

  • 29

    Jun

  • 06

    Jul

  • 11

    Jul

  • 26

    Sep

ANTM

Anthem

$190.17

-3.19 (-1.65%)

18:58
06/23/17
06/23
18:58
06/23/17
18:58
Periodicals
Anthem to pay $115M to settle data breach lawsuits, Reuters reports »

Anthem has agreed to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SVU

Supervalu

$2.94

-0.04 (-1.34%)

18:26
06/23/17
06/23
18:26
06/23/17
18:26
Hot Stocks
Supervalu completes acquisition of Unified Grocers »

Supervalu announced it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GILD

Gilead

$70.52

0.04 (0.06%)

18:14
06/23/17
06/23
18:14
06/23/17
18:14
Periodicals
Gilead no longer a 'value trap,' Barron's reports »

Consistent…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Jun

  • 06

    Jul

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.